May 20, 2019
CLS Therapeutics Announces Poster Presentation at the Frontiers in Cancer Immunotherapy

CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “CELL-FREE TUMOR DNA AND NEUTROPHIL EXTRACELLULAR TRAPS AS NOVEL THERAPEUTIC TARGETS FOR PANCREATIC CANCER” at the Frontiers in Cancer Immunotherapy organized by the New York Academy of Sciences May 14-15, 2019, in New York, New York.

Dr. Tetz’s presentation provided an overview of CLS-014, an engineered gene therapy platform addressing unmet need in pancreatic cancer with multiple follow-up extension opportunities. CLS-014 is an AAV vector that targets cell-free DNA, and has the potential for the treatment of solid tumors. The poster presentation also provided an overview of in vivo animal efficacy evaluating CLS-014 for the treatment of pancreatic cancer.

Poster Session Presentation Details:

 

About the CLS Therapeutics:

CLS Translating the new biology of cell-free DNA into novel therapeutic approaches for multiple cancers, beginning with our first program for pancreatic cancer. PC is the third-leading cause of cancer deaths in the United State with  over  45,000 dying in 2018. It is expected to become the leading cause of cancer mortality already  by 2030. 1-year survival is less than 30%.  5-year survival is less than 8%.

CLS-014 is in silico designed  AAV-based  vector encoding  hyperactive human DNase I transgene cassette. Intravenous injection of the vector with a liver specific promoter leads to long term increase of serum  DNase I activity that cleaves cell-free DNA in the blood and therefore affecting primary tumor growth, metastasis and complications associated with NETosis.

CLS-014  is administered as a single injection with any first-line chemotherapeutic agents.

CLS-Therapeutics presented animal data demonstrating the efficacy of CLS-014 in the treatment of  orthotopic pancreatic  mouse xenograft model. CLS-014 alone, inhibited primary tumor growth and metastasis  and  potentiates nab-paclitaxel.

 

About CLS Therapeutics Inc.

CLS-Therapeutics Inc. is a preclinical-stage biopharmaceutical company focused to deliver on the promise of circulating nucleic acid science to advance a new generation of transformative gene therapies for cancer patients.

Sep 09, 2020

NEW YORK, NY /  September, 2020 / CLS Therapeutics, a preclinical-stage anticancer gene therapy platform company developing novel medicines to bring the curative power of cell-free DNA destruction to patients with tumors, presented preclinical data at the annual meeting of the American Society of Clinical Oncology (ASCO).

Sep 18, 2019

NEW YORK, NY / ACCESSWIRE / September 18, 2019 / CLS Therapeutics, a privately held oncology-focused gene therapy company developing a platform technology based on the identification of a novel therapeutic target that can be utilized for many cancers, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CLS-014 for the treatment of pancreatic cancer.h.

May 10, 2019

CLS Therapeutics Inc., a preclinical-stage biopharmaceutical company developing next-generation gene therapy anticancer drugs, today announced that George Tetz, MD, Ph.D., Chief Executive Officer, presented the poster, “TRANSFORMATIVE ANTICANCER GENE THERAPY PLATFORM ADDRESSING A NOVEL THERAPEUTIC TARGET” at the Cancer Metabolism and Signaling organized by the New York Academy of Sciences May 9, 2019, in New York, New York.